

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

No.: 16/2025/CV-MED

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, April 18, 2025

To: - **State Securities Commission**
 - **Hanoi Stock Exchange**

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Address: 358 Giai Phong, Phuong Liet Ward, Thanh Xuan District, Hanoi

Tax code: 0100108430

Information disclosure person: Mai Nhat Thanh

Position: General Director

Pursuant to Circular No. 96/2020/TT-BTC of the Ministry of Finance on periodic information disclosure of organizations, specific explanations are provided for cases where after-tax profits differ by 10% compared to the same period last year.

Mediplantex National Pharmaceutical Joint Stock Company explains the financial statements for the first quarter of 2025 as follows:

- Net revenue from sales and services in the first quarter of 2025 amounted to 75,429,817,777 VND, representing a decrease of 28%. The cost of goods sold declined by 30%, and gross profit from sales was 18,001,314,561 VND, a reduction of 20% compared to the corresponding period in the first quarter of 2024, attributable to alterations in sales policy.
- Financial income reached 430,258,452 VND, an increase of 32% compared to the equivalent period of the preceding year. Interest expenses were 642,330,809 VND, a substantial decrease of 70%, due to effective debt recovery and a lower average loan balance compared to the previous year.
- Selling expenses totaled 1,214,469,028 VND, reflecting a decrease of 48% compared to the equivalent period of the prior year. Consequently, net profit from business operations was 2,818,040,130 VND, a decline of 44% compared to the corresponding period in the prior year.
- The aforementioned factors collectively resulted in profit after corporate income tax of 2,180,219,673 VND, a decrease of 43% compared to the first quarter of 2024.

Above is the explanation of Mediplantex National Pharmaceutical Joint Stock Company reporting to the State Securities Commission and Hanoi Stock Exchange on the change of indicators in the financial report of the first quarter of 2025 compared to the financial report of the same period last year of Mediplantex National Pharmaceutical Joint Stock Company.

Best regards!

Recipient:

- As above
- Admin

**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT
STOCK COMPANY**

GENERAL DIRECTOR



Mai Nhat Thanh